

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
THERAPEUTIC STUDIES ONLY (TXCA=Y)  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1558	1231	79%	1391	-166	1336	-222
ERLYTX	76	189	249%	213	137	205	129
GI	476	196	41%	221	-254	208	-268
GU	450	381	85%	430	-19	428	-22
GYN	57	0	0%	0	-57	0	-57
LEUK	150	56	37%	63	-86	63	-87
LUNG	524	300	57%	339	-184	331	-193
LYMPH	172	6	3%	6	-165	9	-163
MELAN	55	834	1516%	942	887	943	888
MMYEL	147	64	44%	72	-74	79	-68
OTHER	0	32		36	36	37	37
Total	3665	3289		3713	55	3639	-26

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	37	33	89%	37	0	33	-4
CCD	0	1373		1551	1551	1557	1557
GU	0	0		0	0	0	0
LEUK	69	4	6%	4	-64	5	-64
LUNG	43	490	1140%	553	510	545	502
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	10		11	11	11	11
PREV	0	90		101	101	100	100
SURV	0	79		89	89	84	84
<u>SXQOL</u>	<u>878</u>	<u>12</u>	<u>1%</u>	<u>13</u>	<u>-864</u>	<u>18</u>	<u>-860</u>
Total	1172	2091		2359	1189	2353	1181

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE**  
**ALL ACCRUAL REGISTRATIONS**  
**88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1595	1264	79%	1428	-166	1369	-226
CCD	0	1373		1551	1551	1557	1557
ERLYTX	76	189	249%	213	137	205	129
GI	476	196	41%	221	-254	208	-268
GU	450	381	85%	430	-19	428	-22
GYN	57	0	0%	0	-57	0	-57
LEUK	219	60	27%	67	-151	68	-151
LUNG	567	790	139%	892	325	876	309
LYMPH	225	6	3%	6	-218	9	-216
MELAN	55	834	1516%	942	887	943	888
MMYEL	239	64	27%	72	-166	79	-160
OTHER	0	42		47	47	48	48
PREV	0	90		101	101	100	100
SURV	0	79		89	89	84	84
SXQOL	878	12	1%	13	-864	18	-860
<b>Total</b>	<b>4837</b>	<b>5380</b>		<b>6072</b>	<b>1242</b>	<b>5992</b>	<b>1155</b>

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1012	538	53%	607	-404	578	-434
ERLYTX	76	128	168%	144	68	144	68
GI	418	142	34%	160	-257	154	-264
GU	375	270	72%	305	-69	300	-75
GYN	57	0	0%	0	-57	0	-57
LEUK	122	43	35%	48	-73	50	-72
LUNG	441	205	46%	231	-209	225	-216
LYMPH	129	6	5%	6	-122	9	-120
MELAN	55	444	807%	501	446	502	447
MMYEL	85	63	74%	71	-13	78	-7
OTHER	0	32		36	36	37	37
Total	2770	1871		2109	-654	2077	-693

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	10	33	330%	37	27	33	23
CCD	0	1163		1314	1314	1347	1347
GU	0	0		0	0	0	0
LEUK	69	4	6%	4	-64	5	-64
LUNG	30	353	1177%	398	368	383	353
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	10		11	11	11	11
PREV	0	77		87	87	84	84
SURV	0	49		55	55	53	53
<u>SXQOL</u>	<u>740</u>	<u>12</u>	<u>2%</u>	<u>13</u>	<u>-726</u>	<u>18</u>	<u>-722</u>
Total	994	1701		1919	927	1934	940

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1022	571	56%	645	-376	611	-411
CCD	0	1163		1314	1314	1347	1347
ERLYTX	76	128	168%	144	68	144	68
GI	418	142	34%	160	-257	154	-264
GU	375	270	72%	305	-69	300	-75
GYN	57	0	0%	0	-57	0	-57
LEUK	191	47	25%	53	-137	55	-136
LUNG	471	558	118%	630	159	608	137
LYMPH	182	6	3%	6	-175	9	-173
MELAN	55	444	807%	501	446	502	447
MMYEL	177	63	36%	71	-105	78	-99
OTHER	0	42		47	47	48	48
PREV	0	77		87	87	84	84
SURV	0	49		55	55	53	53
SXQOL	740	12	2%	13	-726	18	-722
Total	3764	3572		4031	274	4011	247

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES  
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	65	1037	1595%	1171	1106	1132	1067
CCD	0	1373		1551	1551	1557	1557
GI	81	27	33%	30	-50	32	-49
GU	215	82	38%	92	-122	90	-125
LEUK	0	4		4	4	5	5
LUNG	53	97	183%	109	56	115	62
LYMPH	7	1	14%	1	-5	2	-5
MELAN	0	747		844	844	852	852
MMYEL	0	64		72	72	79	79
OTHER	0	22		24	24	27	27
PREV	0	90		101	101	100	100
SURV	0	79		89	89	84	84
<u>SXQOL</u>	<u>878</u>	<u>12</u>	<u>1%</u>	<u>13</u>	<u>-864</u>	<u>18</u>	<u>-860</u>
Total	1299	3635		4101	2806	4093	2794

## SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
BREAST	II	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	16	170	333	15.2	Sep-2018
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1		0.2	
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		51		2.3	
		A011202 Breast, Nodal XRT +/- ALND	ALLIANCE			58			
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		87		8.7	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		21		3.2	
		B51 Breast, Regional Nodal XRT	NRG			23			
		B55 Brst, Adj Olaparib for BRCA,TNBC	NRG	03JUL2014:00:00:00		21		1.0	
		E2112 Brst,Adv,Exemestane+/-Entinostat	ECOG-ACR	02JAN2014:00:00:00		42		1.7	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		46		2.3	
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	50	1416	1900	32.7	Jan-2019
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	12	94	1000	12.7	Oct-2023
	OTHER	A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		6		0.8	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		144		0.3	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		10		0.3	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	14	1085	3960	111.8	Dec-2019
	OTHER	S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	18	133	374	13.8	Apr-2019
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	10	131	707	14.8	Jan-2021
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		37		0.0	
		ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		4		0.2	
	OTHER	EAY131 MATCH	ECOG-ACR	12AUG2015:00:00:00		101		3.7	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		10		1.5	
		EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	ECOG-ACRIN	29JAN2016:00:00:00		1		0.0	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.5	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		3		0.2	
		S1505 Panc,Resect, Perioperative Chemo	SWOG	12OCT2015:00:00:00	25	103	112	4.0	Jan-2018
		S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	SWOG	01SEP2016:00:00:00	14	108	143	11.5	Feb-2018
		S1613 mCRC, Adv/Met, TP vs CETIRI	SWOG	09OCT2017:00:00:00	1	0	130		
	II-III	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	ALLIANCE	13JAN2012:00:00:00		132		2.5	
	III	R0848 Panc, Adj, Erlotinib v ChemoRT	NRG	01MAR2014:00:00:00		20		0.0	
GU	II	EA8141 UTUC, HG, Chemo then Surg	ECOG-ACR	27JAN2015:00:00:00		8		0.0	
		S1314 Blad, COXEN Neoadj. Chemo + Cyst	SWOG	11JUL2014:00:00:00	40	233	230	7.2	Nov-2017
		S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	19	56	180	2.8	Jun-2021



## SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	9	21	148	3.2	Mar-2021
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		1		0.2	
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		2		0.0	
		EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	ECOG-ACR	02FEB2017:00:00:00		3		0.5	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		58		2.2	
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	9	51	969	7.2	Jul-2028
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	43	37	38	0.3	Jan-2018
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00		47	44		Sep-2017 Temp Close
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		67		1.5	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		5		0.3	
LUNG	II	R1306 NSCLC,Adv,ALK/EGFR,TargetAgents	NRG	04NOV2013:00:00:00		8		0.0	
		S1400F Non-Match: MEDI4736 + Tremelimumab	SWOG	02OCT2017:00:00:00	1	0	132		
		S1400G HRRD: Talazoparib (BMN 673)	SWOG	07FEB2017:00:00:00	9	32	60	3.3	Jul-2018
		S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	SWOG	18JUL2016:00:00:00	16	44	53	3.0	Jan-2018
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.5	
		S1403 Adv,EGFR-mt,Afatatinib+/-Cetuximab	SWOG	25MAR2015:00:00:00	31	150	605	6.7	Jul-2023
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		29		1.3	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		54		0.7	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACR	18AUG2014:00:00:00		6		0.5	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		26		2.3	
		S1400I Non-Match: Nivo + Ipi vs Nivo	SWOG	18DEC2015:00:00:00	23	245	350	7.8	Dec-2018
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		401		19.3	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	41	1425		25.5	
	PILOT	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	SWOG	03NOV2017:00:00:00	0	0	28		
LYMPH	II	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	SWOG	10AUG2017:00:00:00	3	0	150	0.0	> 15 Yrs
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		4		0.5	
MELAN	II	E3612 MELAN,Adv Ipilimumab±Bevacizumab	ECOG-ACR			6			
		S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	39	185	280	6.3	Jan-2019
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	12	3	77	0.3	> 15 Yrs
		S1607 MELAN, Adv, T-VEC, MK-3475	SWOG	02OCT2017:00:00:00	1	0	64		
		S1616 MELAN, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	4	2	94	0.5	> 15 Yrs
	II-III	EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		1.2	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACR	15DEC2015:00:00:00		23		1.2	
		S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	SWOG	15OCT2015:00:00:00	25	1345	1378	54.5	Nov-2017

**19-NOV-2017 6:10**  
**SWOG OPEN AND TEMPORARILY CLOSED STUDIES**

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
MMYEL	I-II	S1211 MM,High Risk, RVD+/-ELO	SWOG	27OCT2012:00:00:00		142	110		Jun-2016 Temp Close
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		149		5.5	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II	ALLIANCE	26JAN2015:00:00:00		6		0.7	
	II	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	ALLIANCE	02SEP2014:00:00:00		2		0.2	
		A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.0	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		5		0.0	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		7		0.8	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		4		0.5	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
		II-III	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	NRG	27FEB2014:00:00:00		1		0.0
	III	G0286B Adv Endometrial, Metformin/Chemo	NRG			1			
		NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.0	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		4		0.2	
		R1216 HN, Adv, Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
		G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.2	
		N0577 BRN, Glio, Tem vs Tem+RT vsRT+PVC	ALLIANCE			4			
		NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG	04FEB2016:00:00:00		6		0.3	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
		R0920 HN, Adv, Postop IMRT ± Cetuximab	NRG	24DEC2013:00:00:00		11		0.2	
OTHER		EAQ152 Communication & education in tumor profiling	ECOG-ACR	26SEP2016:00:00:00		11		0.3	
PREV	II	EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis	ECOG-ACR	02SEP2016:00:00:00		44		7.3	
	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.0	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	56	164	480	2.8	Feb-2027
OTHER	A211201 Breast Density, MA.32 companion	ALLIANCE	22AUG2012:00:00:00		14		0.0		
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACR	30SEP2015:00:00:00		7		0.7	
	OTHER	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	2	2	817		
		EA9131 Leuk, Strategy to decrease early APL deaths	ECOG-ACR	16AUG2017:00:00:00		2		0.6	
SXQOL	III	S1316 Compar. Effectiv. Trial for MBO	SWOG	09MAR2015:00:00:00	32	124	200	7.7	Aug-2018
		A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		17		0.3	
		A221102 Brst, AI Arthralgia, Testosterone	ALLIANCE	07SEP2012:00:00:00		10		0.0	

Accrual goals assume studies are not terminated early as a result of interim analysis.  
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.  
 Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.  
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
	ERLYTX	Y	ECOG-ACR	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master	S1400	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACR	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	PREV	Y	ALLIANCE	A211201 Breast Density, MA.32 companion	A211201	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	
		Y	ECOG-ACR	EA9131 Leuk, Strategy to decrease early APL deaths	EA9131	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	Y
	MMYEL	Y	SWOG	S1211 MM,High Risk, RVD+/-ELO	S1211	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Ph/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/lpi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1613 mCRC, Adv/Met, TP vs CETIRI	S1613	N	
		Y	SWOG	S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	S1513	N	
		Y	SWOG	S1505 Panc,Resect, Perioperative Chemo	S1505	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG-GI002	N	
		Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	A021501	N	
		Y	ECOG-ACRIN	EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	EA2133	Y	
	GU	Y	SWOG	S1314 Blad, COXEN Neoadj. Chemo + Cyst	S1314	N	
		Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
		Y	ECOG-ACR	EA8141 UTUC, HG, Chemo then Surg	EA8141	N	
	LUNG	Y	SWOG	S1400G HRRD: Talazoparib (BMN 673)	S1400G	N	
		Y	SWOG	S1400F Non-Match: MEDI4736 + Tremelimumab	S1400F	N	
		Y	SWOG	S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	S1507	N	
		Y	NRG	R1306 NSCLC,Adv,ALK/EGFR,TargetAgents	RTOG-1306	N	
	LYMPH	Y	SWOG	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	S1608	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1607 MELAN, Adv, T-VEC, MK-3475	S1607	N	
		Y	SWOG	S1616 MELAN, Adv, Ipilimumab ± Nivolumab	S1616	N	

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	
		Y	ECOG-ACR	E3612 MELAN,Adv Ipilimumab±Bevacizumab	E3612	N	
	OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	
		Y	ALLIANCE	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	A091202	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	A091305	N	
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
	PREV	Y	ECOG-ACR	EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis	EA1141	Y	
PILOT	LUNG	Y	SWOG	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	S1619	N	
II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	
	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LUNG	Y	SWOG	S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab	S1403	N	
		Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	G0286B Adv Endometrial,Metformin/Chemo	GOG-0286B	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
		Y	NRG	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	GOG-0281	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	ALLIANCE	A011202 Breast, Nodal XRT +/- ALND	A011202		
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACR	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
	GI	Y	NRG	R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG-0848	Y	

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA	
						Study	Temp Close
GU	Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y		
	Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y		
	Y	ECOG-ACR	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	EA8143	Y		
	Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y		
LEUK	Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y		
	Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N		
LUNG	Y	SWOG	S1400I Non-Match: Nivo + Ipi vs Nivo	S1400I	Y		
	Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y		
	Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N		
	Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N		
	Y	ECOG-ACR	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N		
LYMPH	Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N		
MELAN	Y	SWOG	S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	S1404	Y		
	Y	ECOG-ACR	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y		
MMYEL	Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y		
OTHER	Y	NRG	R0920 HN, Adv, Postop IMRT ± Cetuximab	RTOG-0920	Y		
	Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N		
	Y	NRG	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	GOG-0263	Y		
	Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y		
	Y	NRG	NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG-GY004	Y		
PREV	Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y		
	Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y		
SURV	Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y		
	Y	ECOG-ACR	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y		
SXQOL	Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y		
	Y	ALLIANCE	A221102 Brst,Al Arthralgia,Testosterone	A221102	Y		

**PHASE III SWOG COORDINATED OPEN STUDIES  
SORTED BY STUDY ID**

Protocol Number	Study	Accrual Goal	Open Stat/Date	Months Open	Accrual as of 01Jan02	Current Accrual	Proj. Annual Accr. Rate	EXPCLOSE	Proj. Study Duration (Years)
S0820 S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV)	480	Y-03/01/13	56	164	164	34	Feb-2027	14.0
S1007 S1007	Breast,Adj,N1,Endocrine+/-Chemo (BREAST)	4000	Y-01/15/11	82	5083	5083	398	Mar-2015	4.2
S1207 S1207	Brst,Adj,Endocrine+/-Everolimus (BREAST)	1900	Y-09/03/13	50	1416	1416	392	Jan-2019	5.4
S1222	Brst,Fulv. +/- Ever. +/- Anastr. (BREAST)	840	T-05/09/14	42	37	37	0	> 15 Yrs	> 15 Yrs
S1400I S1400I	Non-Match: Nivo + Ipi vs Nivo (LUNG)	350	Y-12/18/15	23	245	245	94	Dec-2018	3.0
S1403 S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG)	605	Y-03/25/15	31	150	150	80	Jul-2023	8.3
S1404 S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN)	1378	Y-10/15/15	25	1345	1345	654	Nov-2017	2.1
S1415CD S1415CD	TrACER CSF Standing Order Intervention for FN (CCD)	3960	Y-09/01/16	14	1085	1085	1342	Dec-2019	3.3
S1418 S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST)	1000	Y-11/15/16	12	94	94	152	Oct-2023	6.9
S1501 S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV)	817	Y-09/15/17	2	2	2			
S1602 S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU)	969	Y-02/07/17	9	51	51	86	Jul-2028	11.4

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.